staccani Be happy for the 57% PFS after 18 months for the ONCS/Merck combo.
There are many Melanoma trial types and each has its own strength.
As for your statement I agree.
Comparing IDRA and DVAX trial results vs ONCS is very wrong.
The ONCS MB is not the place to be debating various Melanoma treatments.
The 24 patients that enlisted and were accepted into the ONCS/Merck UCSF trial were recommended to by their doctors as their last hope for their terminal cancers that had no hope.
Market Data 
Markets 
AI
